Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Retrospective, Single Center, Real-World Study Assessing Weight Changes in HIV-Positive Patients Switching from a Tenofovir Disoproxil Fumarate (TDF) to a Tenofovir Alafenamide Fumarate (TAF) Containing Treatment Regimen

Trial Profile

A Retrospective, Single Center, Real-World Study Assessing Weight Changes in HIV-Positive Patients Switching from a Tenofovir Disoproxil Fumarate (TDF) to a Tenofovir Alafenamide Fumarate (TAF) Containing Treatment Regimen

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Oct 2018

At a glance

  • Drugs Tenofovir alafenamide (Primary) ; Tenofovir disoproxil fumarate
  • Indications HIV infections
  • Focus Adverse reactions
  • Acronyms 17-602
  • Most Recent Events

    • 09 Oct 2018 New trial record
    • 29 Sep 2018 Results published in the Infection Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top